Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Support Care Cancer ; 19(2): 261-9, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20148270

RESUMO

PURPOSE: This study aimed to prove the usefulness of the diagnostic plot, using the haemoglobin content of reticulocytes as a measure of functional iron deficiency (FID) and the ferritin index as a measure of iron availability, to customise anaemia treatment in cancer patients. METHODS: Based on results of this plot, cancer patients fulfilling practice guideline criteria to receive erythropoiesis-stimulating agents (ESAs) were allocated to treatment with ESAs alone, iron alone or the combination of both. Primary endpoint was the percentage of patients identified to require iron in addition or as an alternative to ESA therapy. RESULTS: Out of 303 patients screened, 286 were allocated to treatment: 204 patients were normochromic and iron replete and treated with ESAs alone, 22 had both FID and anaemia of chronic disease and were treated with ESAs and parenteral iron, and 60 were iron-depleted and treated with iron only. After 8 weeks, a haemoglobin increase >1 g/dL from baseline was shown by 56% of patients treated with ESAs alone, by 100% of patients receiving the combination, by 50% of normochromic and by 73% of hypochromic iron-depleted patients receiving iron only. Acute phase reaction did not diminish the response rate to ESAs. CONCLUSIONS: The diagnostic plot was superior to transferrin saturation and ferritin in predicting iron availability in hypochromic patients treated with ESAs and proved useful to select treatment for anaemia in cancer patients.


Assuntos
Anemia/diagnóstico , Anemia/tratamento farmacológico , Hematínicos/uso terapêutico , Hemoglobinas/metabolismo , Neoplasias/sangue , Anemia/sangue , Anemia/etiologia , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Biomarcadores/sangue , Diagnóstico Diferencial , Feminino , Ferritinas/sangue , Ferritinas/deficiência , Hematínicos/efeitos adversos , Hemoglobinas/deficiência , Humanos , Ferro/administração & dosagem , Ferro/sangue , Deficiências de Ferro , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológico , Guias de Prática Clínica como Assunto , Estudos Prospectivos , Reticulócitos/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA